Galapagos awarded European Union grant
The PROLIGEN consortium, comprising a number of European companies and universities, aims to improve the regenerative capacity of injured kidneys, using information derived from genomics, proteomics, and functional genomics. Under the terms of the agreement, BioFocus DPI will use its SilenceSelect and FLeXSelect adenoviral libraries and cellular assay expertise to identify targets that can serve as starting points for the development of novel treatment methods for kidney injury. The resulting gene function information will provide the PROLIGEN consortium the necessary tools to deliver new biologicals and cell-based therapies for kidney regeneration.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.